1429 related articles for article (PubMed ID: 37435838)
21. Adverse clinical outcomes associated with double dose clopidogrel compared to the other antiplatelet regimens in patients with coronary artery disease: a systematic review and meta-analysis.
Zhuo X; Zhuo B; Ouyang S; Niu P; Xiao M
BMC Pharmacol Toxicol; 2018 Sep; 19(1):54. PubMed ID: 30176938
[TBL] [Abstract][Full Text] [Related]
22. Ischemic and Bleeding Events Among Patients With Acute Coronary Syndrome Associated With Low-Dose Prasugrel vs Standard-Dose Clopidogrel Treatment.
Shoji S; Sawano M; Sandhu AT; Heidenreich PA; Shiraishi Y; Ikemura N; Ueno K; Suzuki M; Numasawa Y; Fukuda K; Kohsaka S
JAMA Netw Open; 2020 Apr; 3(4):e202004. PubMed ID: 32239221
[TBL] [Abstract][Full Text] [Related]
23. Comparison of Net Clinical Benefit Between Clopidogrel and Ticagrelor Following Percutaneous Coronary Intervention in Patients in China With Acute Coronary Syndrome.
Li D; Sun Y; Ye X; Li L; Chen Y; Wang D
Adv Ther; 2022 Jan; 39(1):754-766. PubMed ID: 34904209
[TBL] [Abstract][Full Text] [Related]
24. Comparative effects of guided vs. potent P2Y12 inhibitor therapy in acute coronary syndrome: a network meta-analysis of 61 898 patients from 15 randomized trials.
Galli M; Benenati S; Franchi F; Rollini F; Capodanno D; Biondi-Zoccai G; Vescovo GM; Cavallari LH; Bikdeli B; Ten Berg J; Mehran R; Gibson CM; Crea F; Pereira NL; Sibbing D; Angiolillo DJ
Eur Heart J; 2022 Mar; 43(10):959-967. PubMed ID: 34918066
[TBL] [Abstract][Full Text] [Related]
25. Fewer gastrointestinal bleeds with ticagrelor and prasugrel compared with clopidogrel in patients with acute coronary syndrome following percutaneous coronary intervention.
Abraham NS; Yang EH; Noseworthy PA; Inselman J; Yao X; Herrin J; Sangaralingham LR; Ngufor C; Shah ND
Aliment Pharmacol Ther; 2020 Aug; 52(4):646-654. PubMed ID: 32657466
[TBL] [Abstract][Full Text] [Related]
26. Triple Antithrombotic Therapy With Aspirin, P2Y12 Inhibitor, and Warfarin After Percutaneous Coronary Intervention: An Evaluation of Prasugrel or Ticagrelor Versus Clopidogrel.
Verlinden NJ; Coons JC; Iasella CJ; Kane-Gill SL
J Cardiovasc Pharmacol Ther; 2017 Nov; 22(6):546-551. PubMed ID: 28279076
[TBL] [Abstract][Full Text] [Related]
27. Comparison of P2Y12 Inhibitors in Acute Coronary Syndromes in the Australian Population.
Hou M; Hyun K; Chew DP; Kritharides L; Amos D; Brieger D
Heart Lung Circ; 2022 Aug; 31(8):1085-1092. PubMed ID: 35589483
[TBL] [Abstract][Full Text] [Related]
28. Clopidogrel versus ticagrelor or prasugrel in patients aged 70 years or older with non-ST-elevation acute coronary syndrome (POPular AGE): the randomised, open-label, non-inferiority trial.
Gimbel M; Qaderdan K; Willemsen L; Hermanides R; Bergmeijer T; de Vrey E; Heestermans T; Tjon Joe Gin M; Waalewijn R; Hofma S; den Hartog F; Jukema W; von Birgelen C; Voskuil M; Kelder J; Deneer V; Ten Berg J
Lancet; 2020 Apr; 395(10233):1374-1381. PubMed ID: 32334703
[TBL] [Abstract][Full Text] [Related]
29. Antiplatelet therapy after coronary artery bypass surgery: five year follow-up of randomised DACAB trial.
Zhu Y; Zhang W; Dimagli A; Han L; Cheng Z; Mei J; Chen X; Wang X; Zhou Y; Xue Q; Hu J; Tang M; Wang R; Song Y; Kang L; Redfors B; Gaudino M; Zhao Q
BMJ; 2024 Jun; 385():e075707. PubMed ID: 38862179
[TBL] [Abstract][Full Text] [Related]
30. Oral Antiplatelet Therapy Administered Upstream to Patients With NSTEMI.
Pollack CV; Peacock WF; Bhandary DD; Silber SH; Bhalla N; Rao SV; Diercks DB; Frost A; Bangalore S; Heitner JF; Johnson C; DeRita R; Khan ND
Crit Pathw Cardiol; 2020 Dec; 19(4):166-172. PubMed ID: 32947379
[TBL] [Abstract][Full Text] [Related]
31. Dabigatran dual therapy with ticagrelor or clopidogrel after percutaneous coronary intervention in atrial fibrillation patients with or without acute coronary syndrome: a subgroup analysis from the RE-DUAL PCI trial.
Oldgren J; Steg PG; Hohnloser SH; Lip GYH; Kimura T; Nordaby M; Brueckmann M; Kleine E; Ten Berg JM; Bhatt DL; Cannon CP
Eur Heart J; 2019 May; 40(19):1553-1562. PubMed ID: 30793734
[TBL] [Abstract][Full Text] [Related]
32. Individualising dual antiplatelet therapy after percutaneous coronary intervention: the IDEAL-PCI registry.
Christ G; Siller-Matula JM; Francesconi M; Dechant C; Grohs K; Podczeck-Schweighofer A
BMJ Open; 2014 Oct; 4(10):e005781. PubMed ID: 25361837
[TBL] [Abstract][Full Text] [Related]
33. Financial Analysis of CYP2C19 Genotyping in Patients Receiving Dual Antiplatelet Therapy Following Acute Coronary Syndrome and Percutaneous Coronary Intervention.
Johnson SG; Gruntowicz D; Chua T; Morlock RJ
J Manag Care Spec Pharm; 2015 Jul; 21(7):552-7. PubMed ID: 26108379
[TBL] [Abstract][Full Text] [Related]
34. Risk of Major Bleeding With Potent Antiplatelet Agents After an Acute Coronary Event: A Comparison of Ticagrelor and Clopidogrel in 5116 Consecutive Patients in Clinical Practice.
Mullen L; Meah MN; Elamin A; Aggarwal S; Shahzad A; Shaw M; Hasara J; Rashid M; Fisher M; Ali T; Patel B; Ding WY; Grainger R; Heseltine T; Kirmani BH; Obeidat M; Kasolo Y; Thatchil J; Khand A
J Am Heart Assoc; 2021 Apr; 10(8):e019467. PubMed ID: 33834845
[TBL] [Abstract][Full Text] [Related]
35. Antiplatelet agents and anticoagulants for hypertension.
Shantsila E; Kozieł-Siołkowska M; Lip GY
Cochrane Database Syst Rev; 2022 Jul; 7():CD003186. PubMed ID: 35900898
[TBL] [Abstract][Full Text] [Related]
36. Prasugrel-based de-escalation of dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (HOST-REDUCE-POLYTECH-ACS): an open-label, multicentre, non-inferiority randomised trial.
Kim HS; Kang J; Hwang D; Han JK; Yang HM; Kang HJ; Koo BK; Rhew JY; Chun KJ; Lim YH; Bong JM; Bae JW; Lee BK; Park KW;
Lancet; 2020 Oct; 396(10257):1079-1089. PubMed ID: 32882163
[TBL] [Abstract][Full Text] [Related]
37. De-escalation from Prasugrel or Ticagrelor to Clopidogrel in Patients with Acute Coronary Syndrome Managed with Percutaneous Coronary Intervention: An Updated Meta-analysis of Randomized Clinical Trials.
Abdelazeem B; Shehata J; Abbas KS; El-Shahat NA; Baral N; Adhikari G; Khan H; Hassan M
Am J Cardiovasc Drugs; 2022 May; 22(3):287-298. PubMed ID: 34651261
[TBL] [Abstract][Full Text] [Related]
38. An analysis of TRITON-TIMI 38, based on the 12 month recommended length of therapy in the European label for prasugrel.
Wilcox R; Iqbal K; Costigan T; Lopez-Sendon J; Ramos Y; Widimsky P
Curr Med Res Opin; 2014 Nov; 30(11):2193-205. PubMed ID: 25025610
[TBL] [Abstract][Full Text] [Related]
39. MULTInational non-interventional study of patients with ST-segment elevation myocardial infarction treated with PRimary Angioplasty and Concomitant use of upstream antiplatelet therapy with prasugrel or clopidogrel--the European MULTIPRAC Registry.
Clemmensen P; Grieco N; Ince H; Danchin N; Goedicke J; Ramos Y; Schmitt J; Goldstein P;
Eur Heart J Acute Cardiovasc Care; 2015 Jun; 4(3):220-9. PubMed ID: 25182465
[TBL] [Abstract][Full Text] [Related]
40. Updates in antiplatelet agents used in cardiovascular diseases.
Cheng JW
J Cardiovasc Pharmacol Ther; 2013 Nov; 18(6):514-24. PubMed ID: 24213473
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]